TachoSil, a surgical patch used for bleeding control
control, delivered $160 million in sales for Takeda in the fiscal year ended March 31, 2020, the company said in a release.
To reduce debt, Takeda has pledged to dispose of $10 billion worth of non-core assets.
Takeda is focusing on five key business areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.
($1 = 0.8439 euros)
(Reporting by Rocky Swift, editing by Louise Heavens)